scholarly journals Prodrug suicide gene therapy for cancer targeted intracellular by mesenchymal stem cell exosomes

2018 ◽  
Vol 144 (4) ◽  
pp. 897-908 ◽  
Author(s):  
Ursula Altanerova ◽  
Jana Jakubechova ◽  
Katarina Benejova ◽  
Petra Priscakova ◽  
Martin Pesta ◽  
...  
2020 ◽  
Vol 42 (10) ◽  
pp. 818-827
Author(s):  
Hiroaki Kenmochi ◽  
Tomohiro Yamasaki ◽  
Shinichiro Koizumi ◽  
Tetsuro Sameshima ◽  
Hiroki Namba

2010 ◽  
Vol 21 (3) ◽  
pp. 241-250 ◽  
Author(s):  
Maria Teresa Lupo-Stanghellini ◽  
Elena Provasi ◽  
Attilio Bondanza ◽  
Fabio Ciceri ◽  
Claudio Bordignon ◽  
...  

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Jae Heon Kim ◽  
Hong Jun Lee ◽  
Yun Seob Song

Current prostate cancer treatment, especially hormone refractory cancer, may create profound iatrogenic outcomes because of the adverse effects of cytotoxic agents. Suicide gene therapy has been investigated for the substitute modality for current chemotherapy because it enables the treatment targeting the cancer cells. However the classic suicide gene therapy has several profound side effects, including immune-compromised due to viral vector. Recently, stem cells have been regarded as a new upgraded cellular vehicle or vector because of its homing effects. Suicide gene therapy using genetically engineered mesenchymal stem cells or neural stem cells has the advantage of being safe, because prodrug administration not only eliminates tumor cells but consequently kills the more resistant therapeutic stem cells as well. The attractiveness of prodrug cancer gene therapy by stem cells targeted to tumors lies in activating the prodrug directly within the tumor mass, thus avoiding systemic toxicity. Therapeutic achievements using stem cells in prostate cancer include the cytosine deaminase/5-fluorocytosine prodrug system, herpes simplex virus thymidine kinase/ganciclovir, carboxyl esterase/CPT11, and interferon-beta. The aim of this study is to review the stem cell therapy in prostate cancer including its proven mechanisms and also limitations.


2021 ◽  
Author(s):  
Moataz Dowaidar

Suicide gene therapy has a long history, and its effectiveness is now under investigation. The bystander death effect therapeutic strategy proved successful in treating malignant glioma; nevertheless, non-replicating viral vectors may not be able to cover a large invading region of glioma cells. Tumor-trophic stem cell migration and viral replication capacities have the potential to overcome the refractory mechanisms of malignant glioma. Surprisingly, the time to response (partial or total response) was delayed for more than 6 months after the initial Toca 511 treatment, reflecting a stronger antitumor immune response. Immunosuppressive cells such myeloid-derived suppressor cells and tumor-associated macrophages were found to be lower in human glioblastoma tissues after treatment. These mechanisms may have a long-term impact on people with malignant glioma. NSCs and MSCs, for example, might be employed to cover glioma cells' more broad invading areas. However, we must investigate which brain stem cells are the most suited. More study is needed to confirm the migratory potential and survival ratio of the implanted stem cells in the brain utilizing comparative analysis. Suicide gene therapy using stem cell migratory capability and/or viral replicating capability for malignant glioma may recapture the spotlight.


Sign in / Sign up

Export Citation Format

Share Document